Swing Brief · 2026-11-19

Swing Brief

01

What matters

What changed

What needs attention

Eligible or blocked

02

Your book

Account: Robinhood Agentic (active scope only). Spendable buying power and reserved cash are not in this snapshot, so remaining ladder intentions are not treated as available cash. Retirement / Roth and other scopes are excluded.

StockSharesValueWeightGain / loss
ASML1.65$2,23851.4%−$351 (-13.6%)
BKNG10.10$1,48934.2%−$111 (-7.0%)
META1.06$62914.4%−$91 (-12.6%)
Total$4,356−$553 (-11.3%)

ASML is 51.4% of the displayed holdings.

Checked Nov 19, 7:48 PM CT. Values use the Thu Nov 19 close. Public Theme Intelligence Invest lane stays percentages-only.

03

Market

MeasureNowRead
S&P 500 vs its 200-day average-2.0%below
50-day average, last month-0.8%falling
VIX (fear gauge)28.4higher than 98% of the past year
Average stock vs the index, last month+3.5%average stock winning
Rates, oil & AI financing

Last month: oil down 15%.

ItemLevel1 wk1 moWhy it matters
Oil
WTI oil82.91-6.6%-14.7%Feeds headline inflation and therefore yields; also energy-sector earnings.
Brent oil89.92-6.2%-17.4%Global benchmark; a wide Brent-WTI gap points to supply stress outside the US.
Credit & dollar
US dollar index103.91+0.7%+2.1%A stronger dollar tightens global financial conditions.
AI financing (stock prices)
LQD (IG corporate bond ETF)103.08+0.0%-0.1%IG bond prices; falls when rates or IG spreads rise.
HYG (high-yield bond ETF)76.53-0.6%-0.6%Junk bond prices; the market's risk appetite for leveraged borrowers.
Oracle (ORCL)110.57-13.0%-14.4%Equity-market proxy for the most levered big AI builder — not a borrowing-cost print.
CoreWeave (CRWV)44.91-20.7%-27.4%Equity-market proxy for a debt-funded GPU cloud; not a bond yield.
Nebius (NBIS)96.92-24.7%-43.5%Equity-market proxy for a neocloud funded by converts and a secured bridge.
Meta (META)596.22-4.4%-14.5%Equity-market proxy, not a bond yield. Meta issued both equity-like paper and notes — see the financing table.

Data through Nov 19. bp = 0.01%. Sources: FRED and Yahoo Finance.

Big Tech AI spending
Recent AI debt deals
Financing (do not sum these rows)

Do not add proposals, future receipts, and cash already received into one 'cash raised' number. $95B was the Oct 26 equity-program headline. $37.5B of $97.5B was a priced-equity plus proposed-ATM mix, not cash in hand.

IssuerInstrumentAmountGross vs netStatusCash receiptCoupon / pref. dividendDilutionSource
METASeries A mandatory convertible depositary shares (6.50%)$12.5B gross (250,000,000 depositary shares)gross $12.5B; net not restated hereclosed2026-10-29 (offering close)6.50% on $1,000 preferred liquidation preference; dividends payable Feb/May/Aug/Nov 15 starting 2027-02-15 through 2029-08-15Converts on or about 2029-08-15 into Class A (or Class C after issuance) at a range; dilutive on conversion, not a completed share count todayMeta 8-K
METAClass A common stock forward saleAbout $25B gross / reported ~46 million shares (cash on settlement, not at initial sale)gross ~$25B; proceeds received when forwards settlepriced; cash not all received at saleupon settlement of each forward, not at initial salen/a (equity forward)Dilutive when forwards settle into Class A (or later Class C)Meta IR press release
METAUSD senior notes$15.0B aggregate principalgross $15.0B principal; five tranches 5.850% 2031, 6.250% 2033, 6.550% 2036, 7.350% 2046, 7.500% 2056closed2026-11-055.850% / 6.250% / 6.550% / 7.350% / 7.500%none (debt)Meta 8-K Nov 5
METAEuro senior notes€9.0B aggregate principalgross €9.0B; six tranches 4.300%–6.400%priced; settlement expected 2026-11-12 (T+5 from 2026-11-04 trade date)expected 2026-11-124.300% 2031, 4.650% 2033, 4.900% 2035, 5.400% 2038, 6.050% 2044, 6.400% 2065none (debt)Meta FWP Nov 4
METAProposed Class C ATMProposed program (press-reported up to ~$60B); not completednone receivedproposed / not begunnone — ATM sales would occur later, expected after Class C tradingn/aWould be dilutive if and when shares are soldMeta IR (proposed; not a completed raise)
ORCLLong-term debt outstanding (reported stock)About $117B long-term debt outstanding / issued (not this week's deal)stock of debt, not a single issuanceoutstandingalready on the balance sheet; not new November cashsee outstanding notes; S&P BBB-noneCNBC / company commentary on outstanding LT debt
ORCLNovember common stock + senior notes$10B common (86,206,897 shares at $116) + $10B notesnet proceeds ~$9.9B equity and ~$10.0B notes after discounts/expensespriced 2026-11-02; expected close 2026-11-04expected 2026-11-04 if closednotes: 7.000% 2029, 7.450% 2031, 7.850% 2033, 8.000% 2037, 8.650% 2046Common offering dilutive; notes are debtOracle IR Nov 2

Meta Class C effective date 2027-01-19; payment date TBD — not the same as the effective date. Do not automatically halve META ladder prices solely because January 19 arrives. Market adjustment and payment date are separate.

Druckenmiller 13F lens (disclosed longs; price-trend badge is not his short book)
Druckenmiller lens: his big positions (13F as of Sep 30, 2026)

His core holdings (kept 3+ quarters) and his largest positions (2%+), grouped by theme. Small one-quarter trades are left out. Filed Nov 16, 2026, holdings as of Sep 30, 2026, next filing due about Feb 15, 2027 (holdings as of Dec 31). SEC filing

A 13F shows only US stocks and options he owned on the last day of the quarter, reported up to 45 days later. No shorts, bonds, currencies or futures, and he may have sold since. Every name below is a disclosed 13F long. The second badge is the current price trend (strong / weak / mixed vs the S&P 500 and the 50-day), not his short book. X lines and patterns are my read of a small sample of posts, not data.

Healthcare & biotech
  • NTRA Nateradisclosed 13F long price trend: weak
    29.2% of portfolio · held all 6 quarters checked · holding steady · vs S&P last month -24%
  • INSM Insmeddisclosed 13F long price trend: strong
    4.2% of portfolio (incl. calls) · held all 6 quarters checked · trimming · vs S&P last month +66%
  • RVMD Revolution Medicinesdisclosed 13F long price trend: weak
    2.0% of portfolio · held 3 quarters in a row · holding steady · vs S&P last month -11%
  • NAMS NewAmsterdam Pharmadisclosed 13F long price trend: weak
    1.8% of portfolio · held all 6 quarters checked · holding steady · vs S&P last month -2%

X: Upbeat but quiet. Mostly biotech specialists talking earnings (Insmed beat and rose); a viral post noticed Natera is nearly a fifth of his book. Not crowded. Natera post Insmed post

Pattern (my read): His classic move: he bought biotech after four bad years when the trend started to turn (his words in February). Health care has now led the S&P for 1 and 3 months, so the move is visible but X still isn't crowded.

vs your Brief: Overlap. Matches Rotation: health care (XLV) is beating the S&P by about 12% over 1 month, 14% over 3 months and 22% over 6 months.

Chips & AI hardware
  • STX Seagatedisclosed 13F long price trend: weak
    9.1% of portfolio (incl. calls) · held 3 quarters in a row · building · vs S&P last month -19%
  • STM STMicrodisclosed 13F long price trend: weak
    1.9% of portfolio · held 4 quarters in a row · trimming · vs S&P last month -0%

X: Loud and crowded. Earnings-week lists, AI spending debates and bubble talk; chip stocks swung hard last week.

Pattern (my read): He kept Taiwan Semi and added STMicro and Seagate, but sold Broadcom, Micron and the small optics names. Owning the makers, not the most crowded AI trades.

vs your Brief: Partly in conflict with the Brief's AI optics and power themes: he sold the optics names, and his power trades (Vistra, GE Vernova, Bloom Energy) lasted only a quarter or two.

Big Tech that earns from AI
  • AMZN Amazondisclosed 13F long price trend: strong
    6.9% of portfolio (incl. calls) · held 5 quarters in a row · building · vs S&P last month +6%

X: The most crowded topic on X. Mixed after Alphabet fell about 12% on earnings (Oct 29) while Amazon held up. Alphabet earnings post

Pattern (my read): He built Amazon fast (about 10x more stock) and opened Alphabet in the quarter to June. Everyone knows these names now, so this is the late, crowded part of the trade.

vs your Brief: No clash with the Brief; Tech (XLK) is weakening vs the S&P on the Rotation tab.

Latin America & emerging markets
  • YPF YPF (Argentina oil)disclosed 13F long price trend: weak
    4.0% of portfolio · held all 6 quarters checked · building · vs S&P last month -29%
  • SE Sea Ltddisclosed 13F long price trend: weak
    3.5% of portfolio · held all 6 quarters checked · building · vs S&P last month -9%
  • EWZ Brazil ETFdisclosed 13F long price trend: weak
    2.8% of portfolio · held 4 quarters in a row · trimming · vs S&P last month -25%
  • TBBB BBB Foods (Mexico)disclosed 13F long price trend: strong
    1.9% of portfolio · held all 6 quarters checked · trimming · vs S&P last month +24%

X: Very negative. Lula won Brazil's runoff on Oct 26 and the Brazil ETF fell about 20% that day; Argentine stocks hit 52-week lows. Brazil post Argentina post

Pattern (my read): This is where his June positions took the hit. We won't know if he sold until the Nov 16 filing. He has said he likes it when he has strong conviction and no one else believes; if he still holds, it's that kind of bet. Watch, don't chase.

vs your Brief: Not a Brief theme. No overlap.

Other big new positions
  • FOXA Fox Corpdisclosed 13F long price trend: mixed
    4.3% of portfolio · held 2 quarters in a row · building · vs S&P last month +5%
  • Unity Software Incdisclosed 13F long price trend: mixed
    3.6% of portfolio · held all 6 quarters checked · building
  • CDW CDWdisclosed 13F long price trend: strong
    2.4% of portfolio (incl. calls) · held 2 quarters in a row · trimming · vs S&P last month +14%

X: Almost no X chatter. Fox reports Monday, Nov 2, before the open.

Pattern (my read): New this quarter and 2% each. Not core yet; check if they survive the Nov 16 filing.

Sold out of last quarter: GOOGL (2.3%), UAL (2.1%), IWM (1.9%), SNDK (1.5%), SPY (1.3%), DAL (1.1%).

Druckenmiller on X: An account named @standuquesne made its first post on Oct 29, saying he invested in trade(xyz), a crypto-futures venue tied to ICE and Hyperliquid (8.9M views). X has not verified it, and some users doubt it is him. Treat it as crypto news, not a stock signal. post

What he said lately: Morgan Stanley interview, published Feb 27, 2026: he moved into biotech because it had been down for years and the trend was turning; 'contrarianism is overrated… I do like it when I have extreme conviction and no one else believes it'; and 'My advantage is not IQ. It's trigger pulling.' Morgan Stanley video

X read Nov 1, 2026, 8:30 PM CT (sample of public X posts). Paper only; nothing here changes a rule or a trade.

AI themes: see Theme Intelligence → (dated if the Invest handoff is not this week).

04

This week

05

Decisions

Sector ETF charts and their TAKE / PASS / DEFER buttons are on the Rotation tab →